Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Argireline (Acetyl Hexapeptide-8)
Overview
Argireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) designed to attenuate neurotransmitter release at the neuromuscular junction. It functions as a competitive inhibitor of the SNARE complex, reducing catecholamine release and potentially diminishing muscle contraction intensity in facial expression muscles.
Mechanism of Action
This mechanism provides a topical alternative rationale to botulinum toxin for addressing expression lines, though with markedly lower potency.
Research Summary & Key Findings
In vitro studies have shown that acetyl hexapeptide-8 can inhibit SNARE complex formation in cell-free systems. Small cosmetic trials have reported modest reductions in periorbital wrinkle depth with twice-daily topical application over 30 days, though methodological rigor and independent replication remain limited. No peer-reviewed clinical trials in dermatology journals have established standardized efficacy benchmarks.
Clinical Status
Argireline (Acetyl Hexapeptide-8) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Argireline"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Argireline"
Registered interventional and observational studies, including status and phase.
- PubChem: "Argireline"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Dermatology
Afamelanotide (Scenesse)
FDA ApprovedA synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a substitution of norleucine a...
View detailsMatrixyl (Palmitoyl Pentapeptide-4)
InvestigationalMatrixyl is a lipopeptide composed of a pentapeptide sequence (Lys-Thr-Thr-Lys-Ser) attached to a palmitic acid moiety t...
View detailsMatrixyl 3000
InvestigationalMatrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapept...
View detailsMatrixyl Synthe'6 (Palmitoyl Tripeptide-38)
InvestigationalPalmitoyl tripeptide-38 is a synthetic lipopeptide designed to stimulate synthesis of six major constituents of the derm...
View detailsNo lawful pathway today
Argireline (Acetyl Hexapeptide-8) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.